Abstract The purpose of this study was to assess primary care physicians' awareness, experience, opinions and preparedness to answer patients' questions regarding direct-to-consumer (DTC) genetic testing. An anonymous survey was mailed to 2,402 family and internal medicine providers in North Carolina. Of the 382 respondents, 38.7% (n=148) were aware of and 15% (n=59) felt prepared to answer questions about DTC genetic tests. Respondents aged 50 or older were more likely to be aware of DTC genetic testing than those less than 40 years old (OR=2.42). Male providers were more likely to feel prepared to answer questions than female providers (OR = 2.65). Among respondents who reportedly were aware, family practitioners were more likely than internists (OR=3.30) to think DTC testing was clinically useful, and 18.9% had patients ask questions or bring in test results. The small percent of physicians who were aware of DTC genetic testing or felt prepared to answer questions about it suggests that education of providers will be necessary if testing becomes more widespread.
Introduction
Personal genome tests that use variants identified by genome wide association studies (GWAS) to assess risk for disease have been offered directly to the consumer over the internet since 2007 (Offit 2008) . There have been discussions within the medical community concerning personal genome testing including: 1) the questionable clinical utility of GWAS tests, 2) the inability to determine absolute disease risk from GWAS data, 3) the absence of specific health recommendations based on the genotypic results of these tests, 4) inadequate informed consent prior to testing, 5) limited explanation of test results, and 6) whether personal genome tests are valid and reliable in comparison to genetic tests that are administered and regulated under the supervision of healthcare providers (Evans and Green 2009; Gross et al. 2009; Kutz 2010; Swan 2010) .
Personal genome testing companies screen for risks of serious diseases such as heart disease, cancer and diabetes. By offering tests directly to the public, healthcare providers are bypassed by people who are ordering and receiving test results. Without proper explanation and informed consent, there is an increased chance that lay individuals will misunderstand their test results (Gollust et al. 2003) . The companies state that they do not provide medical advice based on their test results (23andMe 2011; deCODEme 2011; Pathway Genomics 2011) . One area where companies differ is the extent to which they offer genetic counseling and whether it is performed by a board certified/eligible genetic counselor. While companies with genetic counselors may provide genetic counseling to individuals purchasing tests, the companies without genetic counselors direct patients back to their personal physician, who may not have the knowledge or time to interpret the test results (Baars et al. 2005; Caulfield 2001; Evans et al. 2010; Greendale and Pyeritz 2001; Swan 2010; Williams-Jones 2003) .
Currently, there is a dearth of information about healthcare providers' awareness, experience and perceptions of personal genome testing. Ohata and colleagues (2009) assessed general practitioners' awareness of, and opinions about direct-to-consumer (DTC) genetic tests that can predict an individual's susceptibility to certain adult onset diseases. These researchers found that 38% of general practitioners were aware of DTC genetic testing, primarily from the media, scientific meetings/journals, and the Internet. Less than 1% had ordered a DTC genetic test on a patient. Physicians listed several benefits and some concerns regarding the testing. Noted benefits included convenience, promotion of preventive medicine, providing personalized services, and confidentiality of information. Concerns regarding DTC genetic testing included the reliability of test results, provision of adequate information/counseling, potential misunderstanding of results, inappropriateness of advertising, discrimination in employment and insurance, the possible spread of beliefs such as genetic determinism, and the inappropriate disclosure of patients' genetic information. Kolor and colleagues (2009) reported results from the 2008 DocStyles survey which was sent to internists, family physicians, pediatricians, obstetricians/gynecologists, dermatologists and registered dieticians in the US. These researchers found that less than half (42%) of respondents were aware of personal genome tests offered directly to consumers. Practitioners most often cited the media and the Internet as their source of information about personal genome tests, with medical or scientific journals being a secondary source of information. Less than half of their healthcare provider respondents who were aware of personal genome testing had discussed test results with their patients within the last year or interacted with a patient who had questions about personal genome tests.
Both of these studies surveyed a broad range of healthcare providers at the national level, which could obscure regional differences in attitudes, awareness, and the use of personal genome testing.
Purpose of the Present Study
In this study, North Carolina primary care physicians (PCP) were surveyed to assess their awareness, experience and opinions regarding personal genome testing. Participating PCPs were limited to family physicians and internists because personal genome tests are marketed to healthy adults and generally screen for common diseases seen most frequently in these practice settings. The aims of this study were to assess North Carolina PCPs': 1) awareness, 2) experience, 3) preparedness to answer patient questions, and 4) opinions regarding the perceived clinical usefulness of personal genome testing.
Methods

Participants
A convenience sample of family physicians and internists who were members of the North Carolina Medical Society (NCMS) were recruited to participate. The NCMS is the state's largest physician organization with more than 12,000 members (North Carolina Medical Society 2011). Members include medical students, residents, practicing physicians, retired physicians, and physician assistants. A publically available list containing physician names, medical practice and office addresses was obtained from the NCMS website. Of the 12,000 NCMS members, 1,349 are family medicine providers, and 1,301 are internal medicine providers. Addresses were confirmed and/or updated through a Google search using the physician's name, medical practice, and/or the city in which the practice was located. Of the 2,650 family and internal medicine providers mentioned above, 2,402 addresses were confirmed.
Instrumentation
A novel survey consisting of 30 questions was created by the investigators to meet the goal of this project (Appendix A). Eighteen questions were multiple-choice, seven were dichotomous items (yes/no), three were fill-in-the-blank, and two were in the form of a Likert-type rating scale. Six questions were drawn, with permission, from the 2008 DocStyles survey developed by the Centers for Disease Control and Prevention (CDC). A description of personal genome testing was adapted from the DocStyles survey, and provided in the introduction. It read: "Genetic tests that scan a person's entire genetic makeup for potential health risks are currently being marketed directly to consumers by several different companies (e.g., 23andMe, deCODEme, Navigenics)." Respondents were told that the term "DTC genetic test" would be used as a shorthand way to describe this service.
The survey was divided into six sections. Questions from the DocStyles survey were placed in four sections that assessed the PCP's 1) awareness of DTC genetic testing, 2) experience with patients discussing/bringing in results from DTC genetic tests, 3) opinions about DTC genetic testing, including "perceived clinical usefulness," and 4) medical management (follow-up) after DTC genetic testing. The remaining sections assessed the PCPs' preparedness to answer questions about DTC genetic testing, and participant demographics. Each section consisted of 2-8 questions, and contained a skip pattern that would allow respondents to skip over questions that were not applicable. The survey was piloted with 10 family medicine and internal medicine physicians practicing in Greensboro, NC. No modifications were made.
This study was approved by The University of North Carolina at Greensboro's Institutional Review Board.
Procedures
The physicians and surveys were numbered and a unique ID was created. Cover letters, surveys, informed consent, and a self-addressed stamped envelope (SASE) were mailed to all family practitioners and internists with confirmed addresses. Several tactics were used in the cover letter, to help increase participation in the survey. They included: 1) provision of information about the survey, 2) a request for help or advice, 3) showing positive regard by personalizing the salutation (e.g., Dear Dr. Smith), and 4) saying thank you (Dillman et al. 2009 ). While no compensation was provided to respondents, they were offered a copy of the results once the survey was completed (Dillman et al. 2009; Lydeard 1996) . Other tactics used to maximize survey response included providing alternative ways to return the survey such as a fax number and a link to an online version of the survey housed on Zoomerang, an online survey tool. Physicians completing the survey online were asked to enter their survey number to avoid duplication. When a survey was returned, the physician's name and address were deleted from the key.
Two reminders were sent to non-responders at threeweek intervals. The first reminder was a postcard which referenced the online link. The second reminder contained a cover letter, survey and SASE. Data collection occurred between January and May, 2010.
Data Analysis
Information from the returned surveys was entered into Zoomerang. Data analysis was conducted using PASW Statistics version 18.0 (Chicago, IL). The respondents' personal characteristics and survey responses relating to self-reported awareness, self-reported experience with patients, physician opinion of DTC genetic testing, and preparedness to answer questions about DTC genetic testing were described with frequencies and percentages. The ages of participants was collected within five categories: ≤30, 31-40, 41-50, 51-60, and >60. The age variable was collapsed into three categories. The variable ≤30 and 31-40 was collapsed to ≤40 (younger and less experienced PCPs), the variable 41-50 (middle-aged and moderately experienced PCPs) and 51-60 and >60 was collapsed to ≥51 (older and more experienced PCPs). Board specialty was dichotomized into "family medicine" and "internal medicine" and work setting was dichotomized into "private practice" and "other." Responses to all dependent variables (physician awareness, physician preparedness, and perceived usefulness of DTC genetic testing) were categorized yes and no.
Bivariate associations between each physician's personal characteristic variables and physician awareness, preparedness, and perceived usefulness of DTC genetic testing were calculated using cross-tabulations. Odds ratios were calculated along with a 95% confidence interval in order to explore the strength of the association between the individual predictors and the three outcome variables.
The dichotomous outcome variables of physician awareness, physician preparedness, and clinical usefulness were modeled as a function of independent variables for specific respondent personal characteristics. For all outcome variables, the initial model was formulated by including all of the covariates provided in Table 1 . In order to reduce the initial model to the final reduced model, odds ratio (OR) estimates were used for all personal characteristics that were shown to be predictors of awareness, preparedness, and clinical usefulness. Covariates that were not statistically significant predictors of awareness, preparedness, and clinical usefulness were eliminated from the full model using a step-wise forward regression procedure in a manner that subtraction of the covariates from the model did not alter the odds ratio between any of the predictors and the outcome variable by more than 20%. Based on analysis, age and years in practice were found to be significantly correlated (Pearson r=0.487, p=0.00). Age has a stronger correlation to years in practice, therefore years in practice was eliminated from the model. The aim of this methodology is to identify the strongest simplified model of respondents' personal characteristics associated with the three identified outcome variables. Multivariate adjusted ORs and their 95% confidence interval (CI) were determined by exploring log ORs from the multivariate logistic regression using a forward stepwise likelihood ratio model.
Results
Survey Characteristics
As per the eligibility criteria, surveys were sent to 2,402 PCPs in North Carolina. Fifty surveys were "returned to sender," resulting in 2,352 eligible respondents. In total, 397 surveys were returned to the researchers. Surveys were excluded from the final analysis if they were returned blank (n=10) or the PCP was retired (n=5), resulting in 382 completed surveys. The usable response rate for this study was 16.2% (382/2,352).
Respondents had the option of returning the survey by mail, fax, or completing it on-line. Of the surveys completed, 95.3% were returned by mail (n=364) and 4.7% were completed on-line (n=18). No respondents returned the survey by fax. Respondent demographics are summarized in Table 1 . A total of 382 respondents who completed and returned the survey were included in the final analysis. A post-hoc analysis was conducted to determine statistical power given the sample size of 382 which was 0.80.
Sample Demographics
Approximately two-thirds of the respondents were males (69.6%, n=263). More than half were 41 years of age or older (58.5%, n=221). Similarly, 54.7% (n=205) of the respondents were boarded in family medicine, 32.8% (n= 123) were boarded in internal medicine and 12.5% (n=47) were boarded in other specialties such as pediatrics, geriatrics, etc. Most of the respondents (70.3%, n=211) worked in a private practice setting, and the majority (79.3%, n=237) had been in practice more than 10 years (Table 1 ). The average number of years in practice as a physician was 21.8 (SD=11.7).
PCP Awareness of DTC Genetic Testing
Most of the respondents (61.3% n=234) had never heard or read about DTC genetic testing (Table 2 ). Of those who had heard or read about DTC genetic testing (n=148), the most common sources of information were medical or scientific journals (35.1%, n =52), television (33.1%, n=49), a More than 10 years 237 79.3 a n's do not sum to the total sample size due to missing data No 323 85.0 a n's do not sum to the total sample size due to missing data newspaper article (28.4%, n=42) and the Internet (27.0%, n=40) (Table 2 ). Respondents could indicate more than one answer, and a majority (64.2%, n=95) marked at least two sources of information. There was a strong positive association between respondent age and awareness of DTC genetic testing. Respondents 41-50 years old and 51 years of age and older were almost twice as likely to be aware of DTC genetic testing compared to those who were 40 years of age and younger (Table 3) . Bivariate association was examined between work setting and awareness but no statistically significant associations were found. A multivariate logistic regression analysis using a forward stepwise likelihood ratio model indicates that only the PCPs' age was a significant predictor (p=.01) of respondent awareness of DTC genetic testing; this finding is similar to bivariate analysis results (Table 4 ).
PCP Experience with Patients
A majority of the PCPs who were aware of DTC genetic testing (81.1%, n=120) had never discussed DTC tests with a patient or had a patient bring in results of DTC genetic tests (Table 5 ). Only 18.9% (n=28) of PCPs had at least one patient ask about DTC genetic testing (mean=3 patients, SD=2.4) and only five PCPs had at least one patient bring in test results (mean=2 patients, SD=0.713). Additionally, the number of patients asking questions or bringing in DTC genetic test results comprised significantly less than 10% of the PCPs' patient population. Respondents were given a list of types of patient questions and instructed to indicate which of these their patients have asked them.
Frequencies of each category of questions that were asked of physicians are listed in Table 6 . The most frequent conditions for which patients brought in DTC genetic test results to discuss with their physicians were cancer (n=4), cardiac disease (n=3), neurological diseases (n=3), and single gene disorders (n=3). No respondent remembered which DTC testing company the patients had used for testing.
Follow-up Activities by PCPs Who are Aware of DTC Testing
This section of the survey assessed PCPs follow-up medical management plans for patients who brought in DTC genetic test results. Four of the five PCPs who had patients bring in results reported they did not change their patient's medical management, while the remaining physician recommended lifestyle changes including changes in diet and supplements. Reasons given for choosing not to change patient care were that the test did not indicate the patient was at increased risk for developing the disease (n=1) or that there were no evidence-based medical guidelines respondents could follow that would prevent the disease (n =3). Respondents were asked to choose one answer.
PCP Opinions Regarding Clinical Usefulness
Almost half of the respondents who were aware of DTC genetic testing (42.6%, n=63) thought that testing was clinically useful when formulating medical management plans. Among the PCPs who indicated DTC genetic testing was clinically useful at some level, the majority (84.7%, n= 50) thought it was somewhat useful ( Table 5 ). The 63 respondents who indicated DTC genetic testing was clinically useful were asked about its clinical benefits. The most frequently endorsed benefits were the ability to: 1) offer screening tests (e.g., mammograms, colonoscopies, EKG) at an earlier age to individuals at an increased risk (82.5%, n=52), and 2) offer screening tests more frequently to individuals who are found to be at an increased risk (81.0%, n=51).
The 85 respondents who were aware of DTC genetic testing and indicated that it is not clinically useful endorsed these reasons: 1) no guidelines exist to reduce or alleviate the risk for many diseases (80.0%, n=68), 2), it is too difficult to interpret what the results mean regarding patient care (58.8%, n=50), 3), it will cause more patient anxiety (51.8%, n=44), 4), they would not change a patient's management based on DTC testing (35.3%, n=30), or 5) "Other" (18.8%, n=16). "Other" reasons fell into the following categories: the lack of clinical usefulness of results (n=6), the lack of accuracy of the test results (n=6), and concerns about future insurance coverage for a patient who had DTC genetic testing (n=4).
Of the five respondents who had a patient bring in results, four respondents indicated that DTC genetic testing was not clinically useful. These four endorsed the following reasons: no guidelines exist to reduce or alleviate the risk for many diseases (n=4), it is too difficult to interpret what the results mean regarding patient care (n=3), and it will cause more patient anxiety (n=2). None of the four endorsed the comment "I would not change a patient's management based on DTC testing".
Primary care providers who were aware of DTC genetic testing were also asked what concerns they have about the testing. From a list of 12 concerns (Table 2) , the most common concerns included that: results could increase patient anxiety (87.1%, n=129), patients may interpret the results incorrectly (85.1%, n=126), advertisements may mislead patients (85.1%, n=126), and the clinical utility is questionable (81.8%, n=121).
When asked how likely it was that a patient's DTC genetic test results would influence their care of a patient, those respondents who were aware of DTC genetic testing (n=148, 38.8%) felt DTC genetic test results were likely (33.8%, n=50) or very likely (4.7%, n=7) to influence the (Table 4 ) of preparedness to answer questions about DTC genetic testing. Primary care providers who were ≥51 years of age were significantly more likely to say they were prepared to discuss DTC genetic testing than those who were ≤40 years of age.
Discussion
This is the first regional survey in the United States of primary care physicians concerning their awareness and attitudes about DTC genetic testing. Primary care providers were specifically targeted because 1) it is anticipated that patients in adult primary care offices will increasingly ask questions, or bring in results from this type of genetic testing, 2) DTC genetic testing companies target their tests toward healthy adults, and 3) the conditions companies test for, with few exceptions, are common complex diseases that typically have an adult onset. The present results indicate that approximately 39% of respondents were aware of DTC genetic testing. Their awareness level and sources of information are similar to those reported previously in the literature (Kolor et al. 2009; Ohata et al. 2009 ). While the overall awareness level of DTC genetic testing in this study was similar to other studies, the level of PCP experience with patients inquiring about DTC genetic testing was substantially lower. Only 18.9% (n=28) of PCPs who were aware of DTC genetic testing had ever answered questions or discussed DTC test results with their patients compared to 42% of providers in a national sample of US providers (Kolor et al. 2009) . When looking at how much first-hand experience PCPs in this study had, on average they answered questions from three patients or discussed DTC genetic testing from two patients. These results suggest that, at this time, a minority of North Carolinians may be pursuing DTC personal genome testing or, if they are pursuing testing, that they are not discussing the results with their primary care physicians. This is consistent with other reports indicating a low demand (an estimate of 20,000-30,000 tests purchased world wide from one of the three Almost half of the responding PCPs who were aware of DTC genetic testing felt that it was at least somewhat clinically useful for formulating medical management plans. Therefore, if a PCP feels the test is clinically useful then it is likely the results will influence medical management. Despite a lack of guidelines on how to manage patients based on DTC test results, the ability to offer screening tests more frequently and at earlier ages to those who test positive for adult onset diseases were often endorsed as benefits of the tests. Overall, family practice PCPs were significantly more likely to believe that this technology is clinically useful. One plausible explanation may be that family practice physicians focus on disease prevention and health promotion, which is one of the primary goals of genomic medicine, whereas internists tend to be skilled in the management of patients who have undifferentiated or multi-system disease processes (American Academy of Family Physicians 2006).
Respondents' concerns about patient anxiety, the potential for misinterpretation, and misleading advertising are consistent with those reported in other studies (Ohata et al. 2009) Other concerns were also noted by survey respondents. Despite a lack of evidence of genetic discrimination (Billings et al. 1992) , and the fact that the Genetic Information Non-Discrimination Act went into effect in 2009 (Genetic Information Nondiscrimination Act of 2008), most respondents were concerned about health insurance and employment discrimination. Therefore, important discussion points to include in a PCP education program are the risks of insurance and employment discrimination as well as legislation currently in place to protect against genetic discrimination.
Studies have indicated that patients will seek out their primary care provider to discuss their genetic test results and obtain the appropriate follow-up care (Burke 2004; Holtzman and Watson 1997; Miller et al. 2010; Morren et al. 2007) . Similarly, at least one study has suggested that individuals undergoing personal genome testing expect their physician to help interpret the results (McGuire et al. 2009 ), and DTC companies direct patients to their physician to discuss the test results before acting upon the genetic testing information (23andMe 2011; deCODEme 2011; Pathway Genomics 2011). Therefore, PCPs are most likely going to shoulder the responsibility for discussing this technology with their patients. However, the majority of respondents in this survey indicated they did not feel prepared to answer patient questions (e.g. preparedness) about DTC genetic testing. Similar findings are reported in the literature, as several studies have found that PCPs generally have a lack of knowledge about genetics, genetic testing and genetic counseling (Greendale and Pyeritz 2001; Guttmacher et al. 2001; Suther and Goodson 2003) . Since whole genome scanning is a newer technology, PCPs' knowledge of this topic may be low, resulting in a lack of confidence in assessing risk or managing care.
Study Limitations
Several aspects of this study may have limited generalizability of the findings. In particular, the fact that this is a convenience sample of PCPs, and there was a low response rate (16.2%), it cannot be determined how representative the survey respondents are of the general PCP population in North Carolina. However, this study does provide preliminary findings for a larger comprehensive study. The literature indicates that surveys of general practitioners generally achieve poor response rates (McAvoy and Kaner 1996) . Possible reasons for the low response rate include 1) lack of monetary incentives, 2) the mailed survey was four pages, printed front and back and appeared long, and/or 3) the topic was not of current clinical interest to the PCP population. The gender demographics of this survey resembles the gender distribution of the NCMS membership (i.e. 66% and 73% males in family practice and internal medicine, respectively); these are which is the only demographic characteristics we could compare as the NCMS did not respond to requests for information concerning other demographic characteristics of their members.
Another limitation is that we could not determine the extent to which respondents used a particular resource to obtain information about DTC testing. For instance, some respondents may have had multiple exposures to different sources of information while others had a single exposure. In addition, some may have had brief exposures while others may have researched the topic in more detail. Differences between the various resources may determine whether a PCP feels that explaining DTC genetic testing is easy or complicated. Therefore, one area of future research is to compare and contrast the accuracy and depth of the messages within information sources.
Finally, survey respondents could have misunderstood the type of genetic testing that was the focus of this study. Efforts were made to indicate that the questions pertained to personal genome tests available directly to consumers. However, some questions only included the wording "DTC genetic testing" and respondents could have thought these items referred to any DTC genetic testing (e.g., nutrigenomic genetic testing) or genetic tests where DTC marketing is performed (e.g., Myriad's BRACAnalysis). This confusion could have influenced their responses, thereby raising questions about the validity of the data obtained.
Clinical Implications
Despite the limitations of this study, the findings have implications for clinical practice. Should DTC genetic testing become more widely used, a comprehensive education program may be necessary to increase PCP awareness of DTC genetic testing and help PCPs discuss testing with their patients. Based on the concerns indicated by the respondents, topics to include in an education initiative are guidelines on how to manage patients at increased risk for common disease, information on how to communicate results without unnecessarily increasing patient anxiety, the clinical utility of DTC genetic testing, privacy issues, and patient concerns surrounding health insurance and employment discrimination. Access to genetic counseling may help alleviate some of these concerns. A genetic counselor, or other qualified health professional, can discuss the pros and cons of the test, thus assisting consumers in recognizing both the utility and limitations of personal genome tests (American Society of Human Genetics 2007).
Research Recommendations
This study focused solely on physicians. Other health care professionals, such as physician assistants and nurse practitioners who specialize in primary care, should be surveyed about DTC testing. These providers may see their own patients and may have awareness, experiences and opinions that are distinctly different from those of physicians. Additionally, investigations of the North Carolina consumer population to determine their attitudes and experience with DTC genetic testing may provide some insight into who is being tested in North Carolina and whether the numbers of individuals being tested is equivalent to those who are talking with their providers.
Another area of research would be to identify all of the factors PCPs would take into consideration when preparing management plans based on DTC genetic testing. This study asked the question "In general, do you think DTC genetic testing is currently clinically useful, meaning you would take a patient's test results into consideration when formulating your medical management plan (e.g., when to refer for screening tests, when to refer to a specialist, etc.)?". Since respondents were only able to answer yes or no, it is unknown what other factors they would consider.
A final area of research that arises from these findings involves the factors that make a PCP aware of, and feel prepared to answer questions about DTC genetic testing. In the present study, male respondents and those 51 years or older more were more likely to feel prepared to answer questions. Research in the area of gender differences indicates that men are encouraged to express more assertive and independent behaviors (Heilman 2001) , and at least one study has indicated the tendency for male physicians to overestimate their competence (Lind et al. 2002) . Additionally, the respondents in this study who were age 51 years or older (and typically in practice longer than younger respondents) were more likely to be aware of DTC genetic testing. Development and validation of measures that assess the importance of gender and other factors such as confidence gained through years of practice may help identify reasons for these findings.
Conclusions
Primary care providers surveyed in a regional area reported similar awareness rates but less patient experience than findings of a national survey of providers (Kolor et al. 2009 ). Additionally, most PCPs tended to be skeptical of the clinical utility of DTC genetic testing and did not feel prepared to answer patient questions on the subject. Knowledge of DTC genetic testing issues may increase PCPs' comfort and proficiency discussing such testing and deciding whether to make changes in a patient's care plan based on testing results. Education about clinical utility, privacy issues, and the pros and cons of testing is needed if DTC genetic testing becomes more widely used. Genetic counselors are positioned to play a key role in providing this education for PCPs and for consumers. 
